Weight-Loss Drugmaker Lilly Nears $1.97 Bn AtaiBeckley's Acquisition: Report
The deal would give Lilly access to AtaiBeckley’s Phase 3 DMT nasal spray for treatment-resistant depression, with shares jumping 66% after the report.
- On Thursday, Eli Lilly announced it will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion upfront, expanding its mental health treatment portfolio amid growing sector momentum.
- President Donald Trump's administration ordered faster regulatory reviews of psychedelic treatments and increased federal funding for their research, driving sector momentum.
- New York-based AtaiBeckley is developing BPL-003, a DMT-based nasal spray for treatment-resistant depression currently in Phase 3 clinical trials with results expected in 2029.
- The $6.75 per share acquisition price represents a 26% premium over AtaiBeckley's Wednesday close, reflecting Lilly's aggressive expansion strategy with over $10 billion committed to acquisitions this year.
- Lilly could pay an additional $1 billion if AtaiBeckley's drugs meet specific development and regulatory milestones, positioning the deal as a high-stakes bet on advanced-stage psychedelic treatments.
53 Articles
53 Articles
Eli Lilly to Acquire AtaiBeckley in $3.8 Billion Deal to Expand Mental Health Pipeline
Global pharmaceutical giant Eli Lilly and Company on July 16 announced a $3.8 billion acquisition agreement with AtaiBeckley, a New York City-based clinical-stage biopharmaceutical firm known for its innovative therapeutics in treating mental health conditions. AtaiBeckley has been developing a series of rapid-acting neuroplastogens, a class of drugs used to treat central nervous system disorders by helping brain cells to reorganize neural conne…
Eli Lilly makes $3.8 billion bet on psychedelic drugs
Eli Lilly will buy a psychedelic drug developer for up to $3.8 billion, a sign of rising interest in using the chemicals as psychiatric treatments. AtaiBeckley’s BPL-003 psychedelic nasal spray is in late-stage trials to test its effectiveness against treatment-resistant depression; analysts estimate that if it succeeds, it could generate annual sales of up to $1-$2 billion. The theory is that psychedelic drugs relax strongly held but inappropri…
Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma’s Latest Psychedelic Foray
Big Pharma is taking another trip into psychedelics. On Thursday, Eli Lilly announced an agreement to buy the psychedelic drugmaker AtaiBeckley for $2.8 billion upfront and pay up to $1 billion more if certain conditions are met. The deal gives the world’s largest pharmaceutical company access to BPL-003, AtaiBeckley’s psychedelic-based nasal spray that studies have shown reduces treatment-resistant depression with a single dose, as competitors…
(New York = Yonhap News) Correspondent Lee Ji-heon = U.S. pharmaceutical company Eli Lilly has agreed to acquire mental health treatment developer Ataybecley for up to $3.8 billion (5.6 trillion won)...
Coverage Details
Bias Distribution
- 48% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
